Access to treatment for opioid dependence in rural america: Challenges and future directions

JAMA Psychiatry

Volumn 71, Issue 4, 2014, Pages 359-360

  Sigmon, Stacey C ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; METHADONE; NALTREXONE; OPIATE;

DETOXIFICATION; DRUG DEPENDENCE TREATMENT; EMERGENCY WARD; EVIDENCE BASED PRACTICE; GENERAL PRACTICE; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NOTE; OPIATE ADDICTION; PSYCHOSOCIAL CARE; RURAL POPULATION; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; WESTERN HEMISPHERE;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; FORECASTING; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MEDICATION ADHERENCE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT ADMISSION; PRESCRIPTION DRUGS; RURAL HEALTH SERVICES; TELEMEDICINE; UNITED STATES; WAITING LISTS;

EID: 84898659217     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.4450     Document Type: Note

References (10)

1. Birnbaum HG, White AG, SchillerM, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011; 12 (4): 657-667.
2. Peles E, Schreiber S, Adelson M. Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry. J Addict Med. 2013; 7 (3): 177-182.
3. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008; 23 (9): 1393-1398.
4. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006; 63 (1): 102-109.
5. Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, ParrinoM. Distance traveled and cross-state commuting to opioid treatment programs in the United States [published online July 6, 2011]. J Environ Public Health. doi: 10.1155/2011/948789.
6. Office of National Drug Control Policy (ONDCP). Vermont drug control update. http://www.whitehouse.gov/sites/default/files/docs/state-profile- vermont.pdf. Accessed January 9, 2014.
7. Rosenthal RN, LingW, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013; 108 (12): 2141-2149.
8. Sigmon SC, Dunn KE, Saulsgiver K, et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry. 2013; 70 (12): 1347-1354.
9. Krupitsky E, Nunes EV, LingW, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011; 377 (9776): 1506-1513.
10. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993; 269 (15): 1953-1959.